Cerenome, Inc. (CNSY)
NASDAQ: CNSY · Real-Time Price · USD
0.6427
-0.0272 (-4.06%)
At close: Nov 6, 2026, 4:00 PM EST
0.6651
+0.0224 (3.49%)
After-hours: Nov 6, 2026, 7:58 PM EST
Cerenome Employees
Cerenome had 28 employees as of December 31, 2025. The number of employees increased by 7 or 33.33% compared to the previous year. That makes Cerenome the 37,306th largest employer in the world and 5,207th in the United States.
Employees
28
Change (1Y)
7
Growth (1Y)
33.33%
Revenue / Employee
$150,107
Profits / Employee
-$931,714
Market Cap
4.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 28 | 7 | 33.33% |
| Dec 31, 2024 | 21 | 1 | 5.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 3 | 21.43% |
| Dec 31, 2021 | 14 | 2 | 16.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Senti Biosciences Holdings | 39 |
| AIM ImmunoTech | 21 |
| Imunon | 20 |
| Cardio Diagnostics Holdings | 17 |
| Azitra | 13 |
| Can-Fite BioPharma | 5 |
| Pulmatrix | 2 |
CNSY News
- 4 days ago - Cerenome Secures National In-Network Agreement with Aetna for CNSide® - GlobeNewsWire
- 10 days ago - Cerenome completes enrollment in ReSPECT-GBM study - TheFly
- 10 days ago - Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma - GlobeNewsWire
- 12 days ago - Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases - GlobeNewsWire
- 18 days ago - Cerenome announces new dual mechanism of action for REYOBIQ - TheFly
- 18 days ago - Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™ - GlobeNewsWire
- 4 weeks ago - Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests - GlobeNewsWire
- 4 weeks ago - Cerenome Launches CNSide® CSF Molecular Profile Tests - GlobeNewsWire